Moser, Tobias
Gruber, Joachim
Mylonaki, Eirini
Böhm, Vincent
Schwarzenhofer, Daniel
Tröscher, Anna R.
Lenzenweger, Eva
Krehan, Ingomar
Söllradl, Eva
Leitinger, Markus
Helbok, Raimund
Trinka, Eugen
von Oertzen, Tim J.
Wagner, Judith N. http://orcid.org/0000-0002-0776-6821
Funding for this research was provided by:
Universität Duisburg-Essen
Universitätsklinikum Essen
Article History
Received: 5 July 2024
Revised: 16 September 2024
Accepted: 19 September 2024
First Online: 5 October 2024
Declarations
:
: Tim J von Oertzen has received payment or honoraria for lectures, presentations, or manuscript writing support from Angelini Pharma, Eisai, GW Pharmaceuticals, Jazz Pharma, Livanova, and UCB Pharma and has served on advisory boards for Angelini Pharma, Arvelle Therapeutics, GW Pharmaceuticals, Jazz Pharma, and Zogenix Pharma outside the submitted work. Judith Wagner has received payment or honoraria for lectures, presentations, or travel grants from Boehringer Ingelheim, Janssen-Cilag GmbH, Pfizer Pharma GmbH, Novartis Pharma GmbH, Roche Austria GmbH, and UCB Pharma AG and has served on advisory boards for Janssen-Cilag GmbH and Novartis Pharma GmbH outside the submitted work. Daniel Schwarzenhofer reports an unrestricted grant by Boehringer Ingelheim RCV GmbH & Co. Eugen Trinka reports personal fees from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Medtronic, Biocodex, Bial-Portela & Cª, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, Epilog, UCB, Biogen, Sanofi, Jazz Pharmaceuticals, and Actavis. His institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Österreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. All the other authors report no conflicts of interest.